The Trentonian

Novartis receives FDA approval of Xolair(R) (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients

EAST HANOVER, N.J., April 12, 2021 /PRNewswire/ — Novartis today announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application for Xolair (R) ...
Business Wire

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
Monthly Prescribing Reference

Self-Administration Option Approved for Xolair Prefilled Syringe

Xolair, an anti-immunoglobulin E antibody, is indicated for the treatment of moderate to severe persistent asthma, chronic idiopathic urticaria, and nasal polyps. The Food and Drug Administration (FDA ...
Nasdaq

FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications

– Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment – “Today's approval reflects our ...
Nasdaq

FDA Approves Roche's Xolair Prefilled Syringe For Self-Injection Across All Indications

(RTTNews) - Roche (RHHBY) said Tuesday that it has received an approval from the U.S. Food and Drug Administration for its supplemental Biologics License Application of Xolair or omalizumab prefilled ...